Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA CAR-NK 92 cells in Relapsed/Refractory Multiple Myeloma
NCT03940833Phase 2Unknown
- Sponsor
- Asclepius Technology Group
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BCMA CAR-NK92 cells in multiple myeloma (MM), sponsored by Asclepius Technology Group. Status: unknown.
02
Drugs
BCMA CAR-NK92 cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03940833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03940833.